Overexpression of BCL2, BCL6, VEGFR1 and TWIST1 in Circulating Tumor Cells Derived from Patients with DLBCL Decreases Event-Free Survival

Overexpression of BCL2, BCL6, VEGFR1 and TWIST1 in Circulating Tumor Cells Derived from Patients with DLBCL Decreases Event-Free Survival

Rafael Cerón,1,2 Adolfo Martínez,2 Christian Ramos,3 Adrián De la Cruz,2 Anel García,2 Iveth Mendoza,2 Goujon Palmeros,2 Efreen Horacio Montaño Figueroa,3 Juan Navarrete,4 Silvia Jiménez-Morales,5 Carlos Martinez-Murillo,3 Irma Olarte2 1Posgrado en Ciencias Biológicas, Biomedicina, UNAM, CDMX, Méxic...

Full description

Bibliographic Details
Main Authors:	Cerón R, Martínez A, Ramos C, De la Cruz A, García A, Mendoza I, Palmeros G, Montaño Figueroa EH, Navarrete J, Jiménez-Morales S, Martinez-Murillo C, Olarte I
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-12-01
Series:	OncoTargets and Therapy
Subjects:	biomarkers ctcs lymphoma liquid biopsies.
Online Access:	https://www.dovepress.com/overexpression-of-bcl2-bcl6-vegfr1-and-twist1-in-circulating-tumor-cel-peer-reviewed-fulltext-article-OTT

Similar Items

Clinicopathological analysis of DLBCL/HGBL with MYC, BCL2 and BCL6 gene rearrangement
by: WEI Jing, HE Yaqi, XUE Tian, BAI Qianming, SHUI Ruohong, LU Hongfen, LI Xiaoqiu, YU Baohua
Published: (2023-09-01)

Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.
by: Daruka Mahadevan, et al.
Published: (2014-01-01)

GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner
by: Zhizhou Xia, et al.
Published: (2021-01-01)

Immunohistochemical expression of p53, BCL-2, BAX and VEGFR1 proteins in nephroblastomas A expressão imuno-histoquímica das proteínas p53, BCL-2, BAX e VEGFR1 em nefroblastomas
by: Ana Paula Percicote, et al.
Published: (2013-02-01)

NSO myeloma cell death: Influence of bcl-2 overexpression.
by: Murray, K, et al.
Published: (1996)

Overexpression of Bcl2 and Bcl2L1 Can Suppress Betanodavirus-Induced Type III Cell Death and Autophagy Induction in GF-1 Cells
by: Ang-Jung Lee, et al.
Published: (2022-02-01)

Evaluation of BCL6 and MUM1 Expression in Patients with Diffuse Large B Cell Lymphoma (DLBCL) and Their Correlation with Staging and Prognosis of the Disease
by: Hossein Rahimi, et al.
Published: (2015-01-01)

Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis
by: Defeng Kong, et al.
Published: (2021-01-01)

BCL-XL regulates the timing of mitotic apoptosis independently of BCL2 and MCL1 compensation
by: Chun Yin Yu, et al.
Published: (2024-01-01)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
by: Yosuke Okada, et al.
Published: (2022-02-01)

Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x<sub>L</sub>/Bcl-w Inhibitors
by: Zhe Peng, et al.
Published: (2024-03-01)

Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer
by: Ki-Tae Hwang, et al.
Published: (2021-06-01)

BCL2 overexpression in diffuse large B-cell Lymphoma
by: Hajar Masrour, et al.
Published: (2023-01-01)

Bcl-2 Overexpression in the Internal Spermatic Vein of Patients with Varicocele
by: Jane-Dar Lee, et al.
Published: (2007-01-01)

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
by: Martijn Kerkhofs, et al.
Published: (2020-07-01)

Bioinformatic Analysis of the BCL-xL/BCL2L1 Interactome in Patients with Pancreatic Cancer
by: Dimitrios E. Magouliotis, et al.
Published: (2022-11-01)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
by: D.S. Dalafave, et al.
Published: (2010-08-01)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
by: D.S. Dalafave, et al.
Published: (2010-01-01)

Bcl-B: an “unknown” protein of the Bcl-2 family
by: N. V. Pervushin, et al.
Published: (2023-10-01)

Minimal residual disease assessment of papillary thyroid carcinoma through circulating tumor cell‐based cytology
by: Nadia Innaro, et al.
Published: (2022-12-01)

Comparative evaluation of PD‐L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non‐small cell lung cancer patients
by: Mustafa Abdo, et al.
Published: (2023-05-01)

Cellular, Molecular and Proteomic Characteristics of Early Hepatocellular Carcinoma
by: Athanasios Armakolas, et al.
Published: (2022-10-01)

The impact of bcl-2 overexpression on product MAb glycosylation in hybridoma cultures /
by: 281866 Fadzilah Adibah Abd. Majid, et al.
Published: (2003)

Characterizing Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles in Metastatic Castration-Naive and Castration-Resistant Prostate Cancer Patients
by: Khrystany T. Isebia, et al.
Published: (2022-09-01)

Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
by: Areti Strati, et al.
Published: (2023-06-01)

Roles and Regulation of BCL-xL in Hematological Malignancies
by: Mario Morales-Martínez, et al.
Published: (2022-02-01)

Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer
by: A. N. Markou, et al.
Published: (2023-03-01)

Design of Druglike Small Molecules for Possible Inhibition of Antiapoptotic BCL-2, BCL-W, and BFL-1 Proteins
by: D.S. Dalafave
Published: (2010-09-01)

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
by: Enyuan Shang, et al.
Published: (2018-10-01)

Design of Druglike Small Molecules for Possible Inhibition of Antiapoptotic BCL-2, BCL-W, and BFL-1 Proteins
by: D.S. Dalafave
Published: (2010-01-01)

Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis.
by: Anatasha C Crawford, et al.
Published: (2010-01-01)

50% versus 70%: is there a difference between these BCL2 cut-offs in immunohistochemistry for diffuse large B-cell lymphomas (DLBCL)?
by: Cristiano Claudino Oliveira, et al.
Published: (2020-09-01)

Overexpression of Bcl2 in osteoblasts inhibits osteoblast differentiation and induces osteocyte apoptosis.
by: Takeshi Moriishi, et al.
Published: (2011-01-01)

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice
by: Fenouille, Nina
Published: (2017)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
by: Mike-Andrew Westhoff, et al.
Published: (2022-01-01)

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
by: Reut Yosef, et al.
Published: (2016-04-01)

Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer
by: Andrew A. Davis, et al.
Published: (2019-12-01)

ES-SCLC Patients with PD-L1<sup>+</sup> CTCs and High Percentages of CD8<sup>+</sup>PD-1<sup>+</sup>T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment
by: Anastasia Xagara, et al.
Published: (2024-01-01)

Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes
by: Kiyoko Setoguchi, et al.
Published: (2017-12-01)

Tumor Hypoxia and Circulating Tumor Cells
by: Walter Tinganelli, et al.
Published: (2020-12-01)